Gut microbiome and HIV : relationship with chronic inflammation and fatty liver through metagenomic approaches
HIV infection induces systemic inflammation and microbial dysbiosis, contributing to long-term health complications despite effective antiretroviral therapy (ART). One of the major concerns is the persistence of gut barrier disruption, which leads to microbial translocation and immune activation. Th...
| Autor: | |
|---|---|
| Tipo de recurso: | tesis doctoral |
| Fecha de publicación: | 2025 |
| País: | España |
| Institución: | Universidad Complutense de Madrid (UCM) |
| Repositorio: | Docta Complutense |
| Idioma: | inglés |
| OAI Identifier: | oai:docta.ucm.es:20.500.14352/131021 |
| Acceso en línea: | https://hdl.handle.net/20.500.14352/131021 |
| Access Level: | acceso abierto |
| Palabra clave: | 616.98:578.828 VIH(043.2) Infecciones por virus del SIDA HIV infections Microbiología médica 2420 Virología |
| Sumario: | HIV infection induces systemic inflammation and microbial dysbiosis, contributing to long-term health complications despite effective antiretroviral therapy (ART). One of the major concerns is the persistence of gut barrier disruption, which leads to microbial translocation and immune activation. The gut microbiome plays a crucial role in immune regulation, and its alterations in people with HIV (PWH) have been linked to disease progression, immune dysfunction, and comorbidities like metabolic dysfunction-associated steatotic liver disease (MASLD).Bacterial translocation is a key factor in chronic inflammation, making microbiota-targeted therapies a promising area of research. Strategies such as probiotics, prebiotics, dietary interventions, and fecal microbiota transplantation (FMT) have been explored to mitigate inflammation and restore microbial balance. Among these, FMT has shown potential as a therapeutic intervention. In this work, we found that repeated FMT in PWH on ART was safe and not associated with serious adverse effects. Additionally, it reduced intestinal fatty acid-binding protein (IFABP) levels, a biomarker of intestinal injury predictive of mortality in treated PWH, without affecting T-cell markers... |
|---|